Literature DB >> 12381756

Effects of oral contraceptives on peak exercise capacity.

Gretchen A Casazza1, Sang-Hoon Suh, Benjamin F Miller, Franco M Navazio, George A Brooks.   

Abstract

We examined the effects of menstrual cycle phase and oral contraceptive (OC) use on peak oxygen consumption (VO(2 peak)). Six moderately active, eumenorrheic women (25.5 +/- 1.5 yr) were studied before and after 4 mo of OC. Subjects were tested during the follicular and luteal phases before OC and the inactive and high-dose phases after OC. Before OC, there were no significant differences between the follicular and luteal phases in any of the variables studied. There were also no differences between the inactive and high-dose phases. Dietary composition, exercise patterns, and peak heart rate, minute ventilation, and respiratory exchange ratio did not change with OC use. However, OC use significantly (P </= 0.05) increased body weight (59.6 +/- 2.3 to 61.2 +/- 2.6 kg) and fat mass (13.3 +/- 1.3 to 14.5 +/- 1.3 kg) and decreased VO(2 peak) (-11%, 2.53 +/- 0.21 to 2.25 +/- 0.18 l/min). In conclusion, 1) endogenous ovarian steroids have little effect on VO(2 peak), but 2) the exogenous ovarian steroids in OC decrease peak exercise capacity in moderately physically active young women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381756     DOI: 10.1152/japplphysiol.00622.2002

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  23 in total

Review 1.  Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism.

Authors:  W M Kohrt; R E Van Pelt; W S Gozansky
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Maximal fat oxidation, but not aerobic capacity, is affected by oral contraceptive use in young healthy women.

Authors:  Laurie Isacco; David Thivel; Bruno Pereira; Martine Duclos; Nathalie Boisseau
Journal:  Eur J Appl Physiol       Date:  2014-12-18       Impact factor: 3.078

Review 3.  Applied physiology of female soccer: an update.

Authors:  Naomi Datson; Andrew Hulton; Helena Andersson; Tracy Lewis; Matthew Weston; Barry Drust; Warren Gregson
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

4.  Salivary estradiol, interleukin-6 production, and the relationship to substrate metabolism during exercise in females.

Authors:  Stephen J Ives; Mark Blegen; Mary A Coughlin; Jan Redmond; Tracey Matthews; Vincent Paolone
Journal:  Eur J Appl Physiol       Date:  2011-01-04       Impact factor: 3.078

5.  Sex and nitric oxide bioavailability interact to modulate interstitial Po2 in healthy rat skeletal muscle.

Authors:  Jesse C Craig; Trenton D Colburn; Daniel M Hirai; Michael J Schettler; Timothy I Musch; David C Poole
Journal:  J Appl Physiol (1985)       Date:  2018-01-25

6.  Cardiorespiratory response to exercise in endurance-trained premenopausal and postmenopausal females.

Authors:  Beatriz Rael; Laura Barba-Moreno; Nuria Romero-Parra; Víctor M Alfaro-Magallanes; Eliane A Castro; Rocío Cupeiro; Ana B Peinado
Journal:  Eur J Appl Physiol       Date:  2021-01-03       Impact factor: 3.078

7.  Sex differences in human fatigability: mechanisms and insight to physiological responses.

Authors:  S K Hunter
Journal:  Acta Physiol (Oxf)       Date:  2014-02-25       Impact factor: 6.311

8.  Sex differences in respiratory exercise physiology.

Authors:  A William Sheel; Jennifer C Richards; Glen E Foster; Jordan A Guenette
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 9.  Exercise, Training, and the Hypothalamic-Pituitary-Gonadal Axis in Men and Women.

Authors:  Natalia Cano Sokoloff; Madhusmita Misra; Kathryn E Ackerman
Journal:  Front Horm Res       Date:  2016-06-27       Impact factor: 2.606

10.  Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial.

Authors:  C M Lebrun; M A Petit; D C McKenzie; J E Taunton; J C Prior
Journal:  Br J Sports Med       Date:  2003-08       Impact factor: 13.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.